Shield Therapeutics (STU:1JS) Other Current Liabilities: €22.16 Mil (As of Dec. 2025)


What is Shield Therapeutics Other Current Liabilities?

Shield Therapeutics STU:1JS Other Current Liabilities is €22.16 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Shield Therapeutics's other current liabilities for the quarter that ended in Dec. 2025 was €22.16 Mil.

Shield Therapeutics's quarterly other current liabilities increased from Dec. 2024 (€15.92 Mil) to Jun. 2025 (€29.19 Mil) but then declined from Jun. 2025 (€29.19 Mil) to Dec. 2025 (€22.16 Mil).

Shield Therapeutics's annual other current liabilities increased from Dec. 2023 (€7.95 Mil) to Dec. 2024 (€15.92 Mil) and increased from Dec. 2024 (€15.92 Mil) to Dec. 2025 (€22.16 Mil).

Shield Therapeutics Other Current Liabilities Related Terms

Shield Therapeutics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Shield Therapeutics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Other Current Liabilities Chart

Shield Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 9.17 7.95 15.92 22.16

Shield Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.95 20.93 15.92 29.19 22.16

Shield Therapeutics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €22.16 Mil mean?
Shield Therapeutics (STU:1JS) has a Other Current Liabilities of €22.16 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Shield Therapeutics.
Is Shield Therapeutics' Other Current Liabilities too high?
Shield Therapeutics' current Other Current Liabilities is €22.16 Mil.
How does Shield Therapeutics' Other Current Liabilities compare to ZTS and UTHR?
Shield Therapeutics' Other Current Liabilities of €22.16 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Drug Manufacturers company?
A good Other Current Liabilities depends on the Drug Manufacturers industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Shield Therapeutics. Shield Therapeutics's current Other Current Liabilities is €22.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 32% below its estimated fair value. The current Other Current Liabilities is €22.16 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Other Current Liabilities is €22.16 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shield Therapeutics Business Description

Other Exchanges SHIEF:USASTX:UK1JS:Germany
Address Gateshead Quays, Northern Design Centre, Baltic Business Quarter, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.